Overcoming Resistance to Mitochondrial Apoptosis by BZML-induced Mitotic Catastrophe is Enhanced by Inhibition of Autophagy in A549/Taxol Cells
Overview
Authors
Affiliations
Objectives: Our previous in vitro study showed that 5-(3, 4, 5-trimethoxybenzoyl)-4-methyl-2-(p-tolyl) imidazol (BZML) is a novel colchicine binding site inhibitor with potent anti-cancer activity against apoptosis resistance in A549/Taxol cells through mitotic catastrophe (MC). However, the mechanisms underlying apoptosis resistance in A549/Taxol cells remain unknown. To clarify these mechanisms, in the present study, we investigated the molecular mechanisms of apoptosis and autophagy, which are closely associated with MC in BZML-treated A549 and A549/Taxol cells.
Methods: Xenograft NSCLC models induced by A549 and A549/Taxol cells were used to evaluate the efficacy of BZML in vivo. The activation of the mitochondrial apoptotic pathway was assessed using JC-1 staining, Annexin V-FITC/PI double-staining, a caspase-9 fluorescence metric assay kit and western blot. The different functional forms of autophagy were distinguished by determining the impact of autophagy inhibition on drug sensitivity.
Results: Our data showed that BZML also exhibited desirable anti-cancer activity against drug-resistant NSCLC in vivo. Moreover, BZML caused ROS generation and MMP loss followed by the release of cytochrome c from mitochondria to cytosol in both A549 and A549/Taxol cells. However, the ROS-mediated apoptotic pathway involving the mitochondria that is induced by BZML was only fully activated in A549 cells but not in A549/Taxol cells. Importantly, we found that autophagy acted as a non-protective type of autophagy during BZML-induced apoptosis in A549 cells, whereas it acted as a type of cytoprotective autophagy against BZML-induced MC in A549/Taxol cells.
Conclusions: Our data suggest that the anti-apoptosis property of A549/Taxol cells originates from a defect in activation of the mitochondrial apoptotic pathway, and autophagy inhibitors can potentiate BZML-induced MC to overcome resistance to mitochondrial apoptosis.
Li Z, Ke H, Cai J, Ye S, Huang J, Zhang C Cancer Med. 2024; 13(22):e70267.
PMID: 39571599 PMC: 11581708. DOI: 10.1002/cam4.70267.
Hou Z, Lin S, Du T, Wang M, Wang W, You S Pharmaceuticals (Basel). 2023; 16(5).
PMID: 37242532 PMC: 10221130. DOI: 10.3390/ph16050749.
MiR-217 regulates autophagy through OPG/RANKL/RANK in giant cell tumors.
Meng C, Jiang B, Liu W, Wang L, Zhao Z, Bai R J Orthop Surg Res. 2023; 18(1):346.
PMID: 37165403 PMC: 10170763. DOI: 10.1186/s13018-023-03826-1.
Liu M, Xu C, Qin X, Liu W, Li D, Jia H Front Oncol. 2022; 12:873649.
PMID: 35646704 PMC: 9137409. DOI: 10.3389/fonc.2022.873649.
SIRT1 regulates mitotic catastrophe via autophagy and BubR1 signaling.
Zhao W, Wang Q, Li L, Xie C, Wu Y, Gautam M Mol Cell Biochem. 2022; 477(12):2787-2799.
PMID: 35639235 DOI: 10.1007/s11010-022-04470-9.